NEW YORK, Nov. 9, 2015 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of ZS Pharma, Inc. ("ZS Pharma" or the "Company") (NASDAQ: ZSPH) concerning the proposed acquisition of the Company by AstraZeneca PLC ("AstraZeneca").
Under the terms of the offer, the AstraZeneca would acquire ZS Pharma in a transaction valued at approximately $2.7 billion. Pursuant to the deal, ZS Pharma stockholders would receive $90 in cash per share. According to Yahoo Finance, at least one analyst has set a target price of $110 per share for ZS Pharma stock.
Our investigation concerns whether the ZS Pharma board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company stockholders.
If you own ZS Pharma shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Benjamin I Sachs-Michaels, Esq. Robert I. Harwood, Esq. Harwood Feffer LLP 488 Madison Avenue New York, New York 10022 Phone Numbers: (877) 935-7400 (212)935-7400 Email: email@example.com Website: http://www.hfesq.com Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP